Blockchain Registration Transaction Record

Citius Pharmaceuticals: LYMPHIR Sales Surge, Pipeline Advances

Citius Pharmaceuticals reports $5.6M in LYMPHIR sales, advances Mino-Lok and Halo-Lido pipelines, and expands oncology portfolio with positive trial results.

This news matters because Citius Pharmaceuticals is not only generating revenue from its FDA-approved oncology drug LYMPHIR(TM) but also progressing a pipeline that addresses serious unmet medical needs. The potential approval of Mino-Lok(R) could revolutionize the management of catheter-related bloodstream infections, reducing complications and healthcare costs. Halo-Lido could provide the first prescription treatment for hemorrhoids, a condition affecting millions. For investors and patients alike, Citius represents a promising player in critical care innovation.